Anti-CD20 antibody as consolidation therapy in a patient with primary plasma cell leukemia after high-dose therapy and autologous stem cell transplantation

2001 ◽  
Vol 81 (2) ◽  
pp. 119-123 ◽  
Author(s):  
C. Gemmel ◽  
F. Cremer ◽  
M. Weis ◽  
M. Witzens ◽  
G. Moldenhauer ◽  
...  
Keyword(s):  
Stem Cell ◽  
Stem Cell Transplantation ◽  
Autologous Stem Cell Transplantation ◽  
High Dose ◽  
Consolidation Therapy ◽  
Cell Leukemia ◽  
High Dose Therapy ◽  
Primary Plasma Cell Leukemia ◽  
Cd20 Antibody ◽  
Anti Cd20

High-Dose Therapy and Autologous Stem-Cell Transplantation in Angioimmunoblastic Lymphoma: Complete Remission at Transplantation Is the Major Determinant of Outcome—Lymphoma Working Party of the European Group for Blood and Marrow Transplantation

2008 ◽  
Vol 26 (2) ◽  
pp. 218-224 ◽  
Author(s):  
Charalampia Kyriakou ◽  
Carmen Canals ◽  
Anthony Goldstone ◽  
Dolores Caballero ◽  
Bernd Metzner ◽  
...  
Keyword(s):  
Stem Cell ◽  
Complete Remission ◽  
Stem Cell Transplantation ◽  
Cell Transplantation ◽  
Autologous Stem Cell Transplantation ◽  
Cumulative Incidence ◽  
High Dose ◽  
High Dose Therapy ◽  
Free Survival ◽  
Time Points

PurposePatients with angioimmunoblastic T-cell lymphoma (AITL) have poor prognoses with current conventional chemotherapy. The aim of this study was to evaluate the effect of high-dose therapy (HDT) followed by autologous stem-cell transplantation (ASCT) on patients with AITL.Patients and MethodsWe report a retrospective, multicenter study of 146 patients with AITL who received ASCT. The source of the stem cells was peripheral blood in 143 patients. The conditioning regimen varied, and 74% of the patients received carmustine and 1,3-bis(2-chloroethyl)-1-nitrosourea; etoposide; ara-C; and melphalan chemotherapy.ResultsAfter a median follow-up of 31 months (range, 3 to 174 months), 95 patients (65%) remained alive, and 51 patients (35%) died. Forty-two patients died as a result of disease progression, and nine died as a result of regimen-related toxicity. The cumulative incidence of nonrelapse mortality was 5% and 7% at 12 and 24 months, respectively. The actuarial overall survival (OS) was 67% at 24 months and 59% at 48 months. The cumulative incidence of relapse was estimated at 40% and 51% at 24 and 48 months, respectively. Disease status at transplantation was the major factor that impacted outcome. Patients who received a transplant during first complete remission (CR) had significantly superior progression-free survival and OS. The estimated PFS rates for patients who received their transplants in CR were 70% and 56% at 24 and 48 months, respectively; 42% and 30% for patients with chemotherapy-sensitive disease at those time points, respectively; and 23% at both time points for patients with chemotherapy-refractory disease.ConclusionThis study shows that HDT and ASCT offers the possibility of long-term disease-free survival to patients with AITL. Early transplantation is necessary to achieve optimal results.

High-Dose Therapy and Autologous Stem Cell Transplantation in Relapsed and Refractory Hodgkin’s Disease: Outcome Based on a Prognostic Model

2003 ◽  
Vol 110 (4) ◽  
pp. 173-178 ◽  
Author(s):  
Muzaffar H. Qazilbash ◽  
Marcel P. Devetten ◽  
Jame Abraham ◽  
Joseph P. Lynch ◽  
Charles L. Beall ◽  
...  
Keyword(s):  
Stem Cell ◽  
Stem Cell Transplantation ◽  
Cell Transplantation ◽  
Autologous Stem Cell Transplantation ◽  
Prognostic Model ◽  
Hodgkin’S Disease ◽  
Disease Outcome ◽  
High Dose ◽  
High Dose Therapy ◽  
Dose Therapy

A national study on conditional survival and excess mortality after high dose therapy with autologous stem cell transplantation for non-Hodgkin lymphoma.

2015 ◽  
Vol 33 (15_suppl) ◽  
pp. 8598-8598
Author(s):  
Knut Bjøro Smeland ◽  
Cecilie E Kiserud ◽  
Grete F Lauritzsen ◽  
Anne Kirsti Blystad ◽  
Unn-Merete Fagerli ◽  
...  
Keyword(s):  
Stem Cell ◽  
Stem Cell Transplantation ◽  
Hodgkin Lymphoma ◽  
Autologous Stem Cell Transplantation ◽  
Excess Mortality ◽  
National Study ◽  
High Dose ◽  
Conditional Survival ◽  
High Dose Therapy ◽  
Non Hodgkin Lymphoma
Sign in / Sign up

Export Citation Format

Share Document